DUET-301 / Scopus - LARVOL DELTA

CpG‑aptaDiR: a targeted epigenetic immunotherapy for acute myeloid leukemia (ASGCT 2026) - "Benchmark comparisons included azacitidine and venetoclax, alone or in combination...Wang D, Kaniowski D, Jacek K, Su YL, Yu C, Hall J, Li H, Feng M, Hui S, Kaminska B, DeFranciscis V, Esposito CL, DiRuscio A, Zhang B, Marcucci G, Kuo YH, Kortylewski M. Bi- functional CpG-STAT3 decoy oligonucleotide triggers multilineage differentiation of acute myeloid leukemia in mice...2023. PMID: 36609400; PMCID: PMC9823104."

IO biomarker • Acute Myelogenous Leukemia • Gene Therapies • Hematological Malignancies • Leukemia • Solid Tumor • CALR • CD8 • IDH1 • NPM1 • STAT3 • TLR9

Bi-functional CpG-STAT3 decoy oligonucleotide triggers multilineage differentiation of acute myeloid leukemia in mice. (PubMed, Mol Ther Nucleic Acids) - "Acute myeloid leukemia (AML) cells resist differentiation stimuli despite high expression of innate immune receptors, such as Toll-like receptor 9 (TLR9). In fact, the combination of DNA methyl transferase (DNMT) inhibition using azacitidine with CpG oligonucleotides alone mimicked CpG-STAT3d effects, resulting in AML cell differentiation, T cell activation, and systemic leukemia regression. These findings highlight immunotherapeutic potential of bi-functional oligonucleotides to unleash TLR9-driven differentiation of leukemic cells by concurrent STAT3 and/or DNMT inhibition."

IO biomarker • Journal • Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • B2M • CEBPA • DNMT1 • IL12A • IRF8 • ITGAM • RUNX1 • STAT3 • TLR9